Contact Us | NUWIQ

Octapharma USA, Inc.

121 River Street
Suite 1201
Hoboken, NJ 07030
www.octapharmausa.com
P: 201-604-1130

Customer Service

For general questions about NUWIQ Antihemophilic Factor (Recombinant), reconstitution,
product support, or this site, please contact Octapharma customer service.

P: 866-766-4860
E: uscustomerservice@octapharma.com

Reimbursement

For questions about reimbursement and insurance, please contact Octapharma Reimbursement. Our experienced and knowledgeable professionals are available to provide support to providers, patients, and families.

P: 800-554-4440
F: 240-455-4802
E: usreimbursement@octapharma.com

Drug Safety / Adverse Event Report

For all inquiries relating to drug safety, or to report adverse events, please contact our local
Drug Safety Officer at.

P: 201-604-1137
C: 201-772-4546
F: 201-604-1141

Medical Affairs

For medical information request please fill out the form below and one of our medical affairs representatives will contact you within 48 hours.

* All fields are required

Name*
First Last
Professional Designation*
Affiliation*
Address
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Email*
Enter Email Confirm Email
Phone*
What Octapharma product are you inquiring about?*
Please describe your medical inquiry below
I prefer to be reached by*
I certify*
- This is an unsolicited medical request.

You may also call Octapharma medical affairs and and leave a message at 866-429-4535, or send an e-mail with your unsolicited medical request to usmedicalaffairs@octapharma.com.

Indications and Important Safety Information for NUWIQ .

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ .

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Usage

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications and Adverse Events

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Please see NUWIQ full Prescribing Information. Instructions For Use